Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2025 07:05 ET | Source: Vanqua Bio

Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders, at The International Congress of Parkinson’s Disease and Movement Disorders®

VQ-101 is the first small molecule to demonstrate >70% activation of the lysosomal enzyme glucocerebrosidase (GCase) in GBA-Parkinson’s (GBA-PD) patientsIn the ongoing Phase 1b study in patients...
June 03, 2025 07:02 ET | Source: Vanqua Bio

Vanqua Bio to Present at Upcoming Scientific Conferences

CHICAGO, June 03, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its lead clinical program, VQ-101,...
March 27, 2025 07:00 ET | Source: Vanqua Bio

Vanqua Bio to Present at the AD/PD™ 2025 International Conference

CHICAGO, March 27, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD™ 2025 International Conference on Alzheimer’s and...
December 05, 2024 09:00 ET | Source: Vanqua Bio

Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders

CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit,...
October 09, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders

VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy volunteers, VQ-101 was well tolerated and achieved...
September 18, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio to Participate in Upcoming Scientific Conferences

CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
June 20, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio to Present at Inaugural GBA1 2024 Meeting

CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
April 09, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders

- VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase)- The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients ...
March 13, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio to Present at the Stifel 2024 CNS Days Conference

CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases,...
February 27, 2024 07:30 ET | Source: Vanqua Bio

Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease

Posters to be presented at the AD/PD™ 2024 Conference CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International...